ライフサイエンスコーパス: mantle-cell lymphoma

1 e kinase is a clinically validated target in mantle cell lymphoma.

2 ents with indolent non-Hodgkin's lymphoma or mantle cell lymphoma.

3 VcR-CVAD produced high ORR and CR rates in mantle cell lymphoma.

4 in the clinic to treat multiple myeloma and mantle cell lymphoma.

5 , used for treatment of multiple myeloma and mantle cell lymphoma.

6 elapsing and refractory multiple myeloma and mantle cell lymphoma.

7 formed the treatment of multiple myeloma and mantle cell lymphoma.

8 ma, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma.

9 nhibitor PD0332991 in patients with relapsed mantle cell lymphoma.

10 ody) in patients with relapsed or refractory mantle cell lymphoma.

11 s to evaluate this regimen in follicular and mantle cell lymphoma.

12 ent of patients with relapsed and refractory mantle cell lymphoma.

13 e-agent antitumour activity in patients with mantle cell lymphoma.

14 treatment of multiple myeloma and recurring mantle cell lymphoma.

15 acytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

16 specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

17 te for the treatment of multiple myeloma and mantle cell lymphoma.

18 as clinical activity in multiple myeloma and mantle cell lymphoma.

19 se for the treatment of multiple myeloma and mantle cell lymphoma.

20 remission (PR) in a patient with refractory mantle cell lymphoma.

21 file in patients with relapsed or refractory mantle cell lymphoma.

22 ture on high-dose therapeutic approaches for mantle cell lymphoma.

23 had follicular lymphoma, and one patient had mantle cell lymphoma.

24 ab and idelalisib in relapsed follicular and mantle cell lymphoma.

25 ilability of this procedure to patients with mantle cell lymphoma.

26 llogeneic and autologous transplantation for mantle cell lymphoma.

27 n particular refractory multiple myeloma and mantle cell lymphoma.

28 ated in patients with relapsed or refractory mantle cell lymphoma.

29 ngle-group studies in relapsed or refractory mantle cell lymphoma.

30 ngle-agent therapy in relapsed or refractory mantle cell lymphoma.

31 tients with chronic lymphocytic leukemia and mantle-cell lymphoma.

32 : Burkitt lymphoma, follicular lymphoma, and mantle-cell lymphoma.

33 l types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.

34 in 111 patients with relapsed or refractory mantle-cell lymphoma.

35 gle-agent efficacy in relapsed or refractory mantle-cell lymphoma.

36 tuximab is effective for older patients with mantle-cell lymphoma.

37 R-CHOP in patients with previously untreated mantle-cell lymphoma.

38 clinical trial of adoptive immunotherapy for mantle-cell lymphoma.

39 imus in patients with relapsed or refractory mantle-cell lymphoma.

40 vity in patients with relapsed or refractory mantle-cell lymphoma.

41 atio for ibrutinib in relapsed or refractory mantle-cell lymphoma.

42 ersus temsirolimus in relapsed or refractory mantle-cell lymphoma.

43 rituximab was active as initial therapy for mantle-cell lymphoma.

44 ibody, are active in patients with recurrent mantle-cell lymphoma.

45 ially approved for the treatment of relapsed mantle-cell lymphoma.

46 ve outcomes in patients with newly diagnosed mantle-cell lymphoma.

47 n patients with relapsed indolent B-cell and mantle cell lymphomas.

48 detectable nuclear LEF1 expression, as were mantle cell lymphoma (0 of 5), marginal zone lymphoma (0

49 ma, 0/8 follicular center cell lymphoma, 0/4 mantle cell lymphoma, 0/4 anaplastic large cell (Ki-1+)

50 mide and rituximab in patients with relapsed mantle cell lymphoma (A051201) and relapsed follicular l

51 patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic fa

52 f 56 unclustered IgH-CCND1 translocations in mantle cell lymphoma across the ~ 344-kb bcl-1 breakpoin

53 in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning

54 a randomised, phase 2 study of patients with mantle cell lymphoma aged 18 years or older at 67 clinic

55 s deregulated by chromosome translocation in mantle cell lymphoma and a subset of multiple myeloma.

56 , and Sept 30, 2014, 11 patients (three with mantle cell lymphoma and eight with follicular lymphoma)

57 non-Hodgkin lymphoma subtypes, in particular mantle cell lymphoma and follicular lymphoma.

58 in the biology, pathogenesis, and therapy of mantle cell lymphoma and identifies ongoing areas of cli

59 by nonstereotyped FL BCRs and by the Igs of mantle cell lymphoma and multiple myeloma and suggest th

60 nhibitor of the UPS, bortezomib, in treating mantle cell lymphoma and multiple myeloma has demonstrat

61 Vimentin was also frequently recognized by mantle cell lymphoma and multiple myeloma Igs.

62 rash (two [67%] of three) for patients with mantle cell lymphoma and neutropenia (five [63%] of eigh

63 complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but r

64 Here, we demonstrate that adhesion of mantle cell lymphoma and other non-Hodgkin lymphoma cell

65 alignant B cells isolated from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

66 ezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-

67 A051201 (mantle cell lymphoma) and A051202 (follicular lymphoma)

68 seven of 15 with indolent NHL, and two with mantle-cell lymphoma) and seven of nine patients treated

69 s efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myeloma in vitro.

70 vity of temsirolimus in lymphomas other than mantle cell lymphoma, and supports further evaluation of

71 tment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

72 New insights into mantle cell lymphoma biology may lead to targeted therap

73 this review is to update recent advances in mantle cell lymphoma biology with prognostic and potenti

74 2 trials have shown single-agent activity in mantle-cell lymphoma, breast cancer, liposarcoma, and te

75 than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hemato

76 ycin (mTOR) pathway is a validated target in mantle cell lymphoma, but has not been extensively evalu

77 fferentiated embryonic stem cells, B-CLL and mantle cell lymphoma, but not in major adult tissues apa

78 Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and

79 Thus, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms

80 s in human chronic lymphocytic leukaemia and mantle cell lymphoma cell lines, and patients treated wi

81 In the current study with four mantle cell lymphoma cell lines, we report a new major m

82 1s expression in wild type B cells and human mantle cell lymphoma cell lines.

83 ll) and may be the normal counterpart of the mantle cell lymphoma cell.

84 othesised that adding rituximab could target mantle cell lymphoma cells associated with redistributio

85 ent-derived acute lymphoblastic leukemia and mantle cell lymphoma cells, whereas the IgG1 analogue wa

86 B- and mantle-cell lymphomas, chronic myeloid leukaemia, and mu

87 IMMU-114 was toxic to mantle cell lymphoma, CLL, acute lymphoblastic leukemia,

88 nrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 2

89 Patients with a confirmed mantle cell lymphoma diagnosis (based on CD20-positive a

90 cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and

91 l lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK

92 ular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and

93 in a host of B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, Wal

94 mphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma, expressed CT45.

95 e B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic l

96 Mantle cell lymphoma has a much higher incidence of colo

97 ed for the treatment of multiple myeloma and mantle cell lymphoma; however, in other hematologic mali

98 CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission.

99 r treatment of relapsed multiple myeloma and mantle cell lymphoma) in dy(3K)/dy(3K) mice and in conge

100 ed specific recognition of primary B-CLL and mantle cell lymphoma, including rare drug effluxing chem

101 Patients with relapsed or refractory mantle cell lymphoma ineligible for intensive chemothera

102 tatus > 16%, lactate dehydrogenase > 1N 38%, Mantle Cell Lymphoma International Prognostic Index (low

103 ased on the clinical factors included in the Mantle Cell Lymphoma International Prognostic Index (MIP

104 The Mantle Cell Lymphoma International Prognostic Index (MIP

105 is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIP

106 be shorter for patients presenting with high Mantle Cell Lymphoma International Prognostic Index or l

107 imilar model was created with miR-615-3p and Mantle Cell Lymphoma International Prognostic Index scor

108 I of 2, and 49% with IPI of 3 to 5), as were Mantle Cell Lymphoma International Prognostic Index scor

109 On the basis of the Mantle Cell Lymphoma International Prognostic Index scor

110 variable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were

111 ostic value of miR-29 is comparable with the Mantle Cell Lymphoma International Prognostic Index.

112 ignificantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index.

113 tratified by previous therapy and simplified mantle-cell lymphoma international prognostic index scor

114 Mantle cell lymphoma is a B cell malignancy in which con

115 Mantle cell lymphoma is a generally incurable disease fo

116 Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm th

117 Mantle cell lymphoma is an aggressive non-Hodgkin's lymp

118 Mantle cell lymphoma is characterized by a particularly

119 Mantle cell lymphoma is characterized by dysregulation o

120 The role of transplantation for mantle cell lymphoma is controversial, as the impact on

121 elapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumo

122 Mantle-cell lymphoma is an aggressive B-cell lymphoma wi

123 Mantle-cell lymphoma is generally incurable.

124 Mantle-cell lymphoma is generally incurable.

125 long-term prognosis for older patients with mantle-cell lymphoma is poor.

126 or bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated effi

127 aluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, an

128 of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary

129 ollicular lymphoma (FL) (16.3% [43 of 263]), mantle cell lymphoma (MCL) (6.8% [18 of 263]), and diffu

130 large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fun

131 Mantle cell lymphoma (MCL) accumulates in lymphoid organ

132 ignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leuke

133 broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymp

134 ate the therapeutic efficacy of atiprimod on mantle cell lymphoma (MCL) and elucidate the mechanism b

135 CLL), T-prolymphocytic leukemia (T-PLL), and mantle cell lymphoma (MCL) and is associated with defect

136 nti-CD74 IgG)] show enhanced cytotoxicity in mantle cell lymphoma (MCL) and other lymphoma/leukemia c

137 ouse model, we demonstrated that adhesion of mantle cell lymphoma (MCL) and other non-Hodgkin lymphom

138 monstrated in tumors derived from Granta-519 mantle cell lymphoma (MCL) and Raji Burkitt lymphoma (BL

139 In mantle cell lymphoma (MCL) and some cases of multiple my

140 In this study, we used mantle cell lymphoma (MCL) as a model to characterize th

141 We used mantle cell lymphoma (MCL) as a prototypic blood cancer

142 Y-box 11 (SOX11) expression is specific for mantle cell lymphoma (MCL) as compared with other non-Ho

143 tivation of the translocated CCND1 allele in mantle cell lymphoma (MCL) because of its relocalization

144 et al describe recurrent NOTCH1 mutations in mantle cell lymphoma (MCL) by next-generation sequencing

145 Mantle cell lymphoma (MCL) carries an unfavorable progno

146 ut primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cells are resistant.

147 Mantle cell lymphoma (MCL) cells exhibit increased B-cel

148 ivery of a nucleotide antagonist of eIF4E in mantle cell lymphoma (MCL) cells.

149 of NF-kappaB and chemotherapy resistance in mantle cell lymphoma (MCL) cells.

150 nel of lymphoid cancer cell lines as well as mantle cell lymphoma (MCL) clinical samples.

151 Recent studies show that mantle cell lymphoma (MCL) express aberrant microRNA (mi

152 Although mantle cell lymphoma (MCL) frequently harbors inactivate

153 Mantle cell lymphoma (MCL) has a chromosomal translocati

154 SOX11 overexpression in mantle cell lymphoma (MCL) has been associated with more

155 blood-brain barrier and has activity against mantle cell lymphoma (MCL) in the central nervous system

156 cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16

157 interrogate signaling pathways activated in mantle cell lymphoma (MCL) in vivo, we contrasted gene e

158 Treatment of mantle cell lymphoma (MCL) in younger patients remains a

159 Mantle cell lymphoma (MCL) is a B-cell lymphoma characte

160 Mantle cell lymphoma (MCL) is a B-cell malignancy charac

161 Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymph

162 Mantle cell lymphoma (MCL) is a distinct subtype of non-

163 Mantle cell lymphoma (MCL) is a heterogeneous disease wi

164 Mantle cell lymphoma (MCL) is a highly aggressive B-cell

165 Mantle cell lymphoma (MCL) is a mature B-cell lymphoma c

166 Mantle cell lymphoma (MCL) is a mature B-cell malignancy

167 Mantle cell lymphoma (MCL) is a mostly incurable maligna

168 Mantle cell lymphoma (MCL) is a rare and aggressive form

169 Mantle cell lymphoma (MCL) is an aggressive and incurabl

170 Mantle cell lymphoma (MCL) is an aggressive B-cell malig

171 Mantle cell lymphoma (MCL) is an aggressive B-cell malig

172 Mantle cell lymphoma (MCL) is an aggressive B-cell non-H

173 Mantle cell lymphoma (MCL) is an aggressive malignancy t

174 Mantle cell lymphoma (MCL) is an aggressive tumor, but a

175 ion signature of tumor proliferation rate in mantle cell lymphoma (MCL) is an overriding molecular pr

176 Mantle cell lymphoma (MCL) is an uncommon subtype of non

177 t failure (TTF) and overall survival (OS) in mantle cell lymphoma (MCL) is based on the clinical fact

178 Mantle cell lymphoma (MCL) is characterized by a profoun

179 Mantle cell lymphoma (MCL) is characterized by a t(11;14

180 Mantle cell lymphoma (MCL) is characterized by an aggres

181 Mantle cell lymphoma (MCL) is characterized by an early,

182 Mantle cell lymphoma (MCL) is characterized by the t(11;

183 Mantle cell lymphoma (MCL) is characterized by the uncon

184 ic role of the transcription factor SOX11 in mantle cell lymphoma (MCL) is controversial.

185 entral nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the

186 Mantle cell lymphoma (MCL) is one of the most aggressive

187 Mantle cell lymphoma (MCL) is one of the most aggressive

188 The prognosis for patients with mantle cell lymphoma (MCL) is poor, and at present there

189 ed CD19+/CD20+/CD45+ human lymphoma cells in mantle cell lymphoma (MCL) JeKo-1 model, while the same

190 (D), and 4-hydroxycyclophosphamide (4-HC) in mantle cell lymphoma (MCL) lines.

191 Mantle cell lymphoma (MCL) may be 1 of the few cancers f

192 ase (PI3K) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis, but early-phase

193 matic gene copy number alterations (CNAs) in mantle cell lymphoma (MCL) patients treated first line w

194 spite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are

195 tioning regimen on outcome for patients with mantle cell lymphoma (MCL) remains unknown.

196 There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immu

197 is study, we define the genetic landscape of mantle cell lymphoma (MCL) through exome sequencing of 5

198 cently reported the application of RNAseq to mantle cell lymphoma (MCL) transcriptomes revealing recu

199 tween chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) tumors.

200 Patients with mantle cell lymphoma (MCL) typically respond to initial

201 Mantle cell lymphoma (MCL) usually responds well to init

202 rosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior t

203 Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (

204 ent study, we analyzed telomere length in 73 mantle cell lymphoma (MCL), 55 chronic lymphocytic leuke

205 thesized that 8-NH(2)-Ado would be active in mantle cell lymphoma (MCL), a hematological malignancy c

206 nd apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to

207 Mantle cell lymphoma (MCL), an aggressive subtype of non

208 randomized trials have compared therapies in mantle cell lymphoma (MCL), and the role of aggressive i

209 nt in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but the extent of internaliz

210 lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)

211 In mantle cell lymphoma (MCL), one allele of the cyclin D1

212 is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this

213 , including large B-cell lymphoma (LBCL) and mantle cell lymphoma (MCL), playing an important role in

214 Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary and acquired resista

215 ediated effects of interleukin-21 (IL-21) in mantle cell lymphoma (MCL), providing a preclinical rati

216 advances in the therapy for newly diagnosed mantle cell lymphoma (MCL), relapsed MCL continues to ha

217 For elderly patients with mantle cell lymphoma (MCL), there is no defined standard

218 r understanding about antigen involvement in mantle cell lymphoma (MCL), we analyzed the expression l

219 To obtain insight into the ontogeny of mantle cell lymphoma (MCL), we assessed 206 patients fro

220 g pathway is involved in the pathogenesis of mantle cell lymphoma (MCL), we investigated the phosphor

221 mong 45 patients with relapsed or refractory mantle cell lymphoma (MCL), with manageable tolerability

222 clinical course of the human SOX11-negative mantle cell lymphoma (MCL).

223 ling 40 patients with relapsed or refractory mantle cell lymphoma (MCL).

224 agents for relapsed/refractory patients with mantle cell lymphoma (MCL).

225 b, we noted similar effects in patients with mantle cell lymphoma (MCL).

226 overexpressed in B-cell malignancies such as mantle cell lymphoma (MCL).

227 n has been implicated in the pathogenesis of mantle cell lymphoma (MCL).

228 demonstrated miR-15a/16-1 downregulation in mantle cell lymphoma (MCL).

229 val in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL).

230 th diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

231 issions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL).

232 etan in patients with relapsed or refractory mantle cell lymphoma (MCL).

233 the t(11;14)(q13;q32) translocation found in mantle cell lymphoma (MCL).

234 eukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

235 treating selected NHL, including aggressive mantle cell lymphoma (MCL).

236 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lymphoma (MCL).

237 ment in patients with relapsed or refractory mantle cell lymphoma (MCL).

238 ieved to be essential in the pathogenesis of mantle cell lymphoma (MCL).

239 70% of patients with relapsed and refractory mantle cell lymphoma (MCL).

240 atment for patients with relapsed/refractory mantle cell lymphoma (MCL).

241 comes for ibrutinib-refractory patients with mantle cell lymphoma (MCL).

242 se large B-cell lymphoma (DLCL), and 17 with mantle cell lymphoma (MCL).

243 oxidative stress-mediated drug resistance in mantle cell lymphoma (MCL); however, the biological func

244 mall lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymphoma (MCL; n = 15), low-grade follicular

245 Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma

246 co purified DNA methylation signatures of 82 mantle cell lymphomas (MCL) in comparison with cell subp

247 Mantle-cell lymphoma (MCL) has a variable natural histor

248 omide has shown promise for the treatment of mantle-cell lymphoma (MCL) in preclinical studies.

249 Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma

250 Mantle-cell lymphoma (MCL) is a rather aggressive B-cell

251 Mantle-cell lymphoma (MCL) is a unique subtype of B-cell

252 PURPOSE Mantle-cell lymphoma (MCL) is an aggressive B-cell non-H

253 Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though pa

254 Mantle-cell lymphoma (MCL) is now recognized as a distin

255 an diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models.

256 rabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin'

257 have improved the outcome for patients with mantle-cell lymphoma (MCL), most eventually relapse and

258 ctory diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma (MCL), transformed follicular lymph

259 ) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL).

260 attempt to improve outcome in patients with mantle-cell lymphoma (MCL); however, the importance of i

261 Blastoid-variant mantle-cell lymphoma (MCL-BV), unlike most B-cell non-Ho

262 L], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10).

263 Cyclin D1(-) mantle cell lymphomas (MCLs) are not well characterized,

264 umors and in the vast majority of aggressive mantle cell lymphomas (MCLs).

265 le myeloma (n = 2), T-cell lymphoma (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma

266 sk chronic lymphocytic leukemia (n = 22) and mantle-cell lymphoma (n = 13) received a total lymphoid

267 gkin lymphoma (n=83), and 37% in indolent or mantle-cell lymphoma (n=65).

268 dge, the clinical features of ocular adnexal mantle-cell lymphoma (OA-MCL) have not previously been e

269 a dramatically regressed, and a patient with mantle cell lymphoma obtained an ongoing partial remissi

270 patients with diffuse large B-cell lymphoma, mantle-cell lymphoma, or follicular lymphoma were enroll

271 LBCL (P(trend) = 0.02) and IL10 -1082A>G and mantle cell lymphoma (P(trend) = 0.04).

272 t trials with these agents were conducted in mantle cell lymphoma, pancreatic neuroendocrine tumors a

273 tumor biopsies were reviewed by the European Mantle Cell Lymphoma Pathology Panel to determine Ki-67

274 In mantle cell lymphoma patient samples, we found that lowe

275 One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituxim

276 e response rates and, hopefully, survival in mantle cell lymphoma patients.

277 patients were 73% and 47%, respectively; for mantle-cell lymphoma patients, they were 69% and 53%, re

278 istence of a graft-versus-lymphoma effect in mantle cell lymphoma providing strong scientific rationa

279 Patients with previously untreated mantle cell lymphoma received VcR-CVAD chemotherapy ever

280 small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-

281 stochemical analysis of a cohort of 33 human mantle cell lymphomas shows that elevated expression of

282 tients with chronic lymphocytic leukemia and mantle cell lymphoma signal to apoptosis almost exclusiv

283 igned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligi

284 rapeutic agent for multiple myeloma (MM) and mantle cell lymphoma, suppresses proteosomal degradation

285 nd potentially therapeutic implications, and mantle cell lymphoma treatment approaches and new agents

286 iven to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacc

287 mphocytic leukemia, follicular lymphoma, and mantle cell lymphoma were 5%-10% higher per 5-year incre

288 with autologous stem cell transplantation in mantle cell lymphoma were discouraging, with no clear su

289 71 patients with mantle cell lymphoma were enrolled and 69 were assessabl

290 16, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients rece

291 ed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cell

292 Thirty patients (7 with mantle cell lymphoma) were enrolled and treated.

293 Z138 cells, a B cell line derived from human mantle cell lymphoma, were infused i.v. or s.c.

294 ents with histologically documented relapsed mantle cell lymphoma who had not received previous lenal

295 , USA, and other countries for patients with mantle cell lymphoma who received one previous therapy.

296 mly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not consider

297 al, and overall survival among patients with mantle-cell lymphoma who were younger than 66 years of a

298 nts with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were t

299 a/lymphoma 1 (CCND1/BCL1) is present in most mantle cell lymphomas with the t(11;14)(q13;q32) translo

300 een reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustin